文献速递免疫规划传染病防控与疫情报告

巴基斯坦消除麻疹进展(2000-2018年)

Progress Toward Measles Elimination - Pakistan, 2000-2018.
PubMed 文献 · MMWR Morb Mortal Wkly Rep · 2019-06-07

该报告描述了巴基斯坦2000-2018年消除麻疹的进展与挑战。报告确诊麻疹发病率从2000-2009年均24.6/百万升至2010-2018年均80.4/百万,2013年和2018年出现高峰。

要点

  • MCV1覆盖率从2000年57%升至2017年76%,MCV2从2009年30%升至2017年45%,均未达≥95%目标。
  • 确诊麻疹发病率从2000-2009年均24.6/百万升至2010-2018年均80.4/百万,2013年达230.3/百万。

核心结论

  • 巴基斯坦消除麻疹仍需提高MCV1和MCV2覆盖率、制定策略覆盖未接种社区并增强基于病例的监测敏感性。

研究设计与样本

  • 基于巴基斯坦2000-2018年麻疹消除进展的 descriptive 报告,采用WHO东地中海区域消除麻疹四管齐下策略框架。

主要发现

  • MCV1估计覆盖率从2000年57%升至2017年76%。
  • MCV2于2009年全国引入,覆盖率从2009年30%升至2017年45%。
  • 报告确诊麻疹发病率从2000-2009年平均24.6/百万升至2010-2018年平均80.4/百万,2013年(230.3)和2018年(153.6)出现高峰。
  • 2017和2018年调查后排除的非麻疹疑似病例率分别为2.1/10万和1.5/10万,反映病例报告不足。

关键数值与推荐

  • WHO东地中海区域消除麻疹策略要求每个国家每个区MCV1和MCV2接种覆盖率均≥95%。
  • 策略包括高质量基于病例的麻疹监测和最佳麻疹临床病例管理(包括补充维生素A)。

临床怎么用

  • 需加强常规免疫服务以提高MCV1和MCV2覆盖率至≥95%。
  • 应制定策略识别并覆盖未获得免疫服务的社区。
  • 需提高所有地区基于病例的麻疹监测敏感性。

局限性

  • 2017和2018年调查后排除的非麻疹疑似病例率较低(2.1/10万和1.5/10万),反映病例报告不足。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

In 1997, the 21 countries in the World Health Organization (WHO) Eastern Mediterranean Region* (EMR) passed a resolution during the 41st session of the Regional Committee for the Eastern Mediterranean to eliminate measles† (1). In 2015, this goal was included as a priority in the Eastern Mediterranean Vaccine Action Plan 2016-2020 (2), approved at the 62nd session of the Regional Committee (3). To achieve measles elimination, the WHO Regional Office for the Eastern Mediterranean developed the following four-pronged strategy: 1) achieve ≥95% vaccination coverage with the first dose of measles-containing vaccine (MCV) among children in every district of each country through routine immunization services; 2) achieve ≥95% vaccination coverage with a second MCV dose in every district of each country either through implementation of a routine 2-dose vaccination schedule or through supplementary immunization activities (SIAs)§; 3) conduct high-quality, case-based measles surveillance in all countries; and 4) provide optimal measles clinical case management, including dietary supplementation with vitamin A (4). Pakistan, an EMR country with a population of approximately 200 million, accounts for nearly one third of the overall EMR population. This report describes progress and challenges toward measles elimination in Pakistan during 2000-2018. During the study period, estimated coverage with the first MCV dose (MCV1) increased from 57% in 2000 to 76% in 2017. The second MCV dose (MCV2) was introduced nationwide in 2009, and MCV2 coverage increased from 30% in 2009 to 45% in 2017. During 2000-2018, approximately 232.5 million children received doses of MCV during SIAs. Reported confirmed measles incidence increased from an average of 24.6 per 1 million persons during 2000-2009 to an average of 80.4 during 2010-2018, with peaks in 2013 (230.3) and 2018 (153.6). In 2017 and 2018, the rates of suspected cases discarded as nonmeasles after investigation were 2.1 and 1.5 per 100,000 population, reflecting underreporting of cases. To achieve measles elimination, additional efforts are needed to increase MCV1 and MCV2 coverage, develop strategies to identify and reach communities not accessing immunization services, and increase sensitivity of case-based measles surveillance in all districts.

来源:MMWR Morb Mortal Wkly Rep,查看原文。版权归原作者所有。

引用

  1. Mere MO, Goodson JL, Chandio AK, et al. Progress Toward Measles Elimination - Pakistan, 2000-2018. MMWR Morb Mortal Wkly Rep. 2019. PMID: 31170125. doi:10.15585/mmwr.mm6822a4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。